Galapagos NV (Euronext & LSE: GLPG) and Cancer Research Technology (“CRT”), specialists in oncology drug discovery and commercialization, a wholly owned company of Cancer Research UK, announced today that they have entered into a new collaboration in anti-cancer drug discovery research. Under the terms of the agreement Galapagos’ service division BioFocus will perform medicinal chemistry services on a series of CRT anti-cancer drug programs. In return, CRT will fund the work of four BioFocus scientists throughout 2006.